Most Read

1n 2019, Astellas and FibroGen have also received Japanese approval for roxadustat for the treatment of anaemia in adult patients with CKD and on dialysis. FibroGen now secures

City of Hope will assess the investigational vaccine, dubbed COH04S1, in healthy volunteers aged between 18 and 55 who have not had Covid-19. The investigational vaccine is being

Under the deal, OncoImmune shareholders will be eligible to secure sales-based payments and payments contingent on the achievement of certain regulatory milestones. Recently, the biopharmaceutical company announced positive

The high-level results from an interim analysis, including 131 Covid-19, have shown no hospitalisations or severe cases of the disease in participants receiving the vaccine. AZD1222, co-invented by

The companies have submitted a request to the FDA to secure FDA EUA status for BNT162b2 mRNA vaccine candidate against SARS-CoV-2. The Covid-19 vaccine is expected to be

The EUA status facilitates distribution and emergency use of baricitinib in combination with remdesivir in hospitalised adult and paediatric patients two years of age or older with suspected

The data analysis showed a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (primary infection), as well as in participants with and without prior SARS-CoV-2

With the closing of the deal, MyoKardia now operates as a wholly-owned subsidiary of BMS. The deal provides BMS with MyoKardia’s mavacamten, which is a potential first-in-class cardiovascular

The status was based on efficacy and safety results from HPTN 083 phase IIb/III randomised, multicentre, double-blind and clinical trial. The study compared long-acting and injectable cabotegravir to